Pathology: mML - L1 - BRAF wild;
mML - L1 - BRAF wild | ||||
IMspire-170, 2020 | CheckMate 066, 2015 | CheckMate 069 (BRAF wild type), 2015 | ||
atezolizumab plus cometinib | 1 | T1 | ||
nivolumab alone | 1 | T1 | ||
nivolumab plus ipilimumab | 1 | T1 | ||
pembrolizumab alone | 0 | T0 | ||
dacarbazine | 0 | T0 | ||
ipilimumab alone | 0 | T0 |